[1] RAGHU G, REMY-JARDIN M, MYERS J L,et al.Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline[J].Am J Respir Crit Care Med, 2018,198(5):e44-e68. [2] KREUTER M, POLKE M, WALSH S L F,et al.Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonization[J].Eur Respir J,2020,55(4):1901760. [3] SPAGNOLO P, KROPSKI J A, JONES M G,et al.Idiopathic pulmonary fibrosis: disease mechanisms and drug development[J].Pharmacol Ther,2021,222:107798. [4] STEFANO J T, GUEDES L V, DE SOUZA A A A, et al. Usefulness of collagen type IV in the detection of significant liver fibrosis in nonalcoholic fatty liver disease[J].Ann Hepatol,2021,20:100253. [5] OSOKINA A, KARETNIKOVA V, POLIKUTINA O,et al.Prognostic potential of cardiac structural and functional parameters and N-terminal propeptide of type III procollagen in predicting cardiac fibrosis one year after myocardial infarction with preserved left ventricular ejection fraction[J].Aging (Albany NY),2021,13(1):194-203. [6] COLLARD H R, RYERSON C J, CORTE T J, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report[J].Am J Respir Crit Care Med,2016,194(3):265-275. [7] PHAN T H G, PALIOGIANNIS P, NASRALLAH G K,et al.Emerging cellular and molecular determinants of idiopathic pulmonary fibrosis[J].Cell Mol Life Sci,2021,78(5):2031-2057. [8] 李惠萍.感染和免疫因素在特发性肺纤维化急性加重中的作用[J].内科急危重症杂志,2015,21(5):321-322,326. [9] AWANO N, JO T, YASUNAGA H, et al.Body mass index and in-hospital mortality in patients with acute exacerbation of idiopathic pulmonary fibrosis[J].ERJ Open Res,2021,7(2):00037-2021. [10] SOMOGYI V, CHAUDHURI N, TORRISI S E,et al.The therapy of idiopathic pulmonary fibrosis: what is next? [J].Eur Respir Rev,2019,28(153):190021. [11] SHENDEROV K, COLLINS S L, POWELL J D, et al. Immune dysregulation as a driver of idiopathic pulmonary fibrosis[J].J Clin Invest,2021,131(2):e143226. [12] ISHIBA H, SUMIDA Y, SEKO Y, et al. Type IV collagen 7S is the most accurate test for identifying advanced fibrosis in NAFLD with type 2 diabetes[J].Hepatol Commun,2020,5(4):559-572. [13] MAK K M, MEI R. Basement membrane type iv collagen and laminin: an overview of their biology and value as fibrosis biomarkers of liver disease[J]. Anat Rec: Hoboken,2017,300(8):1371-1390. [14] WILSON S E, SHIJU T M, SAMPAIO L P, et al. Corneal fibroblast collagen type IV negative feedback modulation of TGF beta: a fibrosis modulating system likely active in other organs[J].Matrix Biol, 2022,109:162-172. [15] URUSHIYAMA H, TERASAKI Y, NAGASAKA S,et al.Role of α1 and α2 chains of type IV collagen in early fibrotic lesions of idiopathic interstitial pneumonias and migration of lung fibroblasts[J].Lab Invest,2015,95(8):872-885. [16] MOSCA A, COMPARCOLA D, ROMITO I,et al.Plasma N-terminal propeptide of type III procollagen accurately predicts liver fibrosis severity in children with non-alcoholic fatty liver disease[J].Liver Int,2019,39(12):2317-2329. [17] LIU L, SHI Q, LIU X,et al.Attenuation of myocardial fibrosis using molecular hydrogen by inhibiting the TGF-β signaling pathway in spontaneous hypertensive rats[J].Am J Hypertens,2022,35(2):156-163. [18] GHOUL B E, SQUALLI T, SERVAIS A,et al.Urinary procollagen III aminoterminal propeptide (PIIINP): a fibrotest for the nephrologist[J].Clin J Am Soc Nephrol,2010,5(2):205-210. [19] HEIKKILÄ H P, KrAFFT E, JESPERS P, et al. Procollagen type III amino terminal propeptide concentrations in dogs with idiopathic pulmonary fibrosis compared with chronic bronchitis and eosinophilic bronchopneumopathy[J].Vet J,2013,196(1):52-56. [20] SHENG G, CHEN P, WEI Y, et al. Viral infection increases the risk of idiopathic pulmonary fibrosis: a meta-analysis[J].Chest,2020,157(5):1175-1187. |